Cargando…

Switching to ziv-aflibercept in resistant diabetic macular edema non responsive to ranibizumab injection

BACKGROUND: Diabetic macular edema (DME) is a leading cause of visual loss in diabetic patients and is managed using multiple anti-vascular endothelial growth factor (VEGF) agents such as bevacizumab, ranibizumab and aflibercept. The present study evaluates effectiveness of intravitreal injection of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nawar, Amin E., Wasfy, Tamer, Shafik, Heba M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9241277/ https://www.ncbi.nlm.nih.gov/pubmed/35768859 http://dx.doi.org/10.1186/s12886-022-02503-x

Ejemplares similares

Pilot study of ziv-aflibercept in myopic choroidal neovascularisation patients
por: Nawar, Amin E., et al.
Publicado: (2020)

Use of ziv-aflibercept in diabetic macular edema in a Ghanaian population
por: Braimah, Imoro Zeba, et al.
Publicado: (2022)

Ziv-aflibercept in macular disease
por: Mansour, Ahmad M, et al.
Publicado: (2015)

Intravitreal ziv-aflibercept for macular edema following retinal vein occlusion
por: Paulose, Remya, et al.
Publicado: (2016)

Switching to Aflibercept in Diabetic Macular Edema Not Responding to Ranibizumab and/or Intravitreal Dexamethasone Implant
por: Herbaut, Antoine, et al.
Publicado: (2017)

Role of peripheral pan-retinal photocoagulation in diabetic macular edema treated with intravitreal ziv-aflibercept
por: Mansour, Ahmad M, et al.
Publicado: (2019)

Ziv-aflibercept in Diabetic Macular Edema: Relation of Subfoveal Choroidal Thickness with Visual and Anatomical Outcomes
por: Moradian, Siamak, et al.
Publicado: (2023)

Conversion to aflibercept for diabetic macular edema unresponsive to ranibizumab or bevacizumab
por: Lim, Laurence S, et al.
Publicado: (2015)

Faricimab for Diabetic Macular Edema in Patients Refractory to Ranibizumab or Aflibercept
por: Ohara, Hiromi, et al.
Publicado: (2023)

Intravitreal ziv-aflibercept for recurrent macular edema secondary to central retinal venous occlusion
por: Chhablani, Jay
Publicado: (2015)

One-year outcomes of ziv-aflibercept for macular edema in central retinal vein occlusion
por: Eldeeb, Mohab, et al.
Publicado: (2017)

Intravitreal aflibercept versus intravitreal ranibizumab for the treatment of diabetic macular edema
por: Fouda, Sameh Mosaad, et al.
Publicado: (2017)

Comparisons of Efficacy of Intravitreal Aflibercept and Ranibizumab in Eyes with Diabetic Macular Edema
por: Shimizu, Norihiro, et al.
Publicado: (2017)

Comparison of Intravitreal Aflibercept and Ranibizumab following Initial Treatment with Ranibizumab in Persistent Diabetic Macular Edema
por: Demircan, Ali, et al.
Publicado: (2018)

Comment on: Intravitreal ziv-aflibercept for recurrent macular edema secondary to central retinal venous occlusion
por: Sen, Alok, et al.
Publicado: (2015)

Real Life Multicenter Comparison of 24-Month Outcomes of Anti-VEGF Therapy in Diabetic Macular Edema in Turkey: Ranibizumab vs. Aflibercept vs. Ranibizumab-Aflibercept Switch
por: Kucukevcilioglu, Murat, et al.
Publicado: (2023)

Extended Injection Intervals after Switching from Ranibizumab to Aflibercept in Macular Edema due to Central Retinal Vein Occlusion
por: Nghiem-Buffet, Sylvia, et al.
Publicado: (2018)

Evaluation of ranibizumab and aflibercept for the treatment of diabetic macular edema in daily clinical practice
por: Plaza-Ramos, Pablo, et al.
Publicado: (2019)

Effectiveness of the Use of Three-Dose Intravitreal Ziv-Aflibercept in the Management of Diabetic Macular Edema in a Real-Life Setting
por: Munayco-Guillén, Fernando, et al.
Publicado: (2023)

Real-World Injection Frequency and Cost of Ranibizumab and Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema
por: Kiss, Szilárd, et al.
Publicado: (2020)

Intravitreal ziv-aflibercept in diabetic vitreous hemorrhage
por: Mansour, Ahmad M., et al.
Publicado: (2020)

Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema: Exploratory Retrospective Analysis
por: Pessoa, Bernardete, et al.
Publicado: (2021)

Comparison of the Effect of Ranibizumab and Aflibercept on Changes in Macular Choroidal Thickness in Patients Treated for Diabetic Macular Edema
por: Sarda, Valérie, et al.
Publicado: (2020)

Retinal Toxicity of Intravitreal Injection of Ziv-Aflibercept in Albino Rabbits
por: Ramon, Dan, et al.
Publicado: (2018)

Safety profiles of anti-VEGF drugs: bevacizumab, ranibizumab, aflibercept and ziv-aflibercept on human retinal pigment epithelium cells in culture
por: Malik, Deepika, et al.
Publicado: (2014)

Aflibercept versus Ranibizumab as a Second Line Therapy After Bevacizumab for Diabetic Macular Edema
por: Alsaedi, Nasser G, et al.
Publicado: (2021)

Ziv-aflibercept in metastatic colorectal cancer
por: Patel, Anuj, et al.
Publicado: (2013)

Prolongation of injection interval after switching therapy from ranibizumab to aflibercept in Japanese patients with macular edema secondary to branch retinal vein occlusion
por: Tagami, Mizuki, et al.
Publicado: (2017)

CHANGES IN PLASMA VASCULAR ENDOTHELIAL GROWTH FACTOR LEVEL AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB, AFLIBERCEPT, OR RANIBIZUMAB FOR DIABETIC MACULAR EDEMA
por: Hirano, Takao, et al.
Publicado: (2018)

Switching to Conbercept in Diabetic Macular Edema After Unsatisfactory Response to Previous Intravitreal Injection of Ranibizumab
por: Xing, Peiyu, et al.
Publicado: (2023)

Intravitreal injection of ziv-aflibercept in the treatment of choroidal and retinal vascular diseases
por: HodjatJalali, Kamran, et al.
Publicado: (2017)

Evaluation of contrast sensitivity and other visual function outcomes in diabetic macular edema patients following treatment switch to aflibercept from ranibizumab
por: Nixon, Donald R, et al.
Publicado: (2018)

One-year results of switching to aflibercept for persistent diabetic macular edema resistant to bevacizumab
por: Abouhussein, Mahmoud Alaa, et al.
Publicado: (2021)

Prolongation of injection interval after switching therapy from ranibizumab to aflibercept in Japanese patients with macular edema secondary to branch retinal vein occlusion [Corrigendum]
Publicado: (2017)

Ziv-Aflibercept Use in Metastatic Colorectal Cancer
por: Rodriguez, Mabel
Publicado: (2013)

Fusion proteins for treatment of retinal diseases: aflibercept, ziv-aflibercept, and conbercept
por: de Oliveira Dias, João Rafael, et al.
Publicado: (2016)

Acquired perforating collagenosis associated with ranibizumab injection and succesfully switched to aflibercept
por: Kanra, Ayse Yagmur, et al.
Publicado: (2018)

Changes in metamorphopsia following intravitreal aflibercept injection for diabetic macular edema
por: Murakami, Tomoya, et al.
Publicado: (2022)

Aflibercept versus ranibizumab for treating persistent diabetic macular oedema
por: ROA Vandekerckhove, Kristof
Publicado: (2015)

Retinal pigment epithelium rip following single intravitreal ziv-aflibercept injection
por: Singh, Sumit Randhir, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_qk9keckdv3bb3drvv4rk6p49l5